Bausch Health reported adjusted earnings of US$1.77 per share in the third quarter, beating the supplied calendar estimate of US$1.24. Revenue rose 9.7% from a year earlier, and the company raised its 2026 outlook.
Bausch Health Companies Inc. (TSX: BHC) reported results for the quarter ended September 30, 2026, after markets closed on October 28. Adjusted earnings per share (EPS) came in 42.7% above the calendar estimate. Revenue reached US$2.94 billion, up from US$2.68 billion a year earlier. The company also raised its full-year revenue and adjusted EBITDA forecasts. This was its third estimate beat in the past four comparable quarters. See the Bausch Health stock page for more on BHC.TO.
Recent earnings trend
Advertisement
Bausch Health Companies Inc
BHC.TO
BHC.TO
Bausch Health Companies Inc
WealthAwesomeMarket cap
$3.62B
52W high
$11.08
52W low
$6.10
1W change
+6.73%
Beta
0.37
Analyst Price Targets
Based on analyst covering BHC · as of Sep 17, 2026
Wall Street analysts forecast BHC stock price to fall 27.5% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.01
-27.5% Upside
Current Price
C$9.67
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
37.8%
Annualized
90-Day Vol
66.8%
Annualized
Trend (90d)
+0.9%
Annualized drift
90d Mean
C$9.70
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.68 | C$8.49 – C$11.03 |
| 60 trading days | C$9.69 | C$8.06 – C$11.66 |
| 90 trading days | C$9.70 | C$7.74 – C$12.16 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Analyst coverage: 5 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-10-28 | 1.7700 | 1.2400 | +42.7% |
| 2026-06-30 | 2026-07-29 | 1.2600 | 1.0100 | +24.8% |
| 2026-03-31 | 2026-04-29 | 0.7800 | 0.6900 | +13.0% |
| 2025-12-31 | 2026-02-18 | 1.1000 | 1.2100 | -9.1% |
| 2025-09-30 | 2025-10-29 | 1.1600 | 1.0600 | +9.4% |
| 2025-06-30 | 2025-07-30 | 0.9100 | 0.9400 | -3.2% |
Advertisement
Investor takeaway: Bausch Health paired stronger-than-expected earnings and revenue with higher 2026 guidance. Salix helped drive growth, and operating cash flow increased. The company also plans to redeem about US$643 million in 8.5% notes due in 2027 using cash on hand. Investors should balance those gains against the negative trailing EPS and profit margin in the supplied fundamentals snapshot, and the difference between the latest share price and the average analyst target.
US$1.77 adjusted EPS
Adjusted EPS was 42.7% above the supplied calendar estimate of US$1.24. Revenue reached US$2.94 billion, up 9.7% from a year earlier. The company’s news release coverage used a different comparison: US$1.77 against a US$1.27 consensus. The estimate used matters when assessing the size of the earnings beat.
Bull case
Revenue grew across several businesses. Salix was up 16.1% from a year earlier, while Bausch + Lomb rose 7.3%. Management raised its 2026 revenue outlook to US$10.975 billion–US$11.175 billion and its adjusted EBITDA outlook to US$4.315 billion–US$4.415 billion. Company news also reported that quarterly operating cash flow more than doubled year over year.
Bear case
The large quarterly earnings beat doesn’t change the company’s weak trailing profitability measures. The supplied snapshot shows trailing 12-month EPS of -US$4.08 and a profit margin of -10.12%. The average analyst target of C$7.01 is 27.5% below the last close of C$9.67. The planned note redemption will use cash on hand, so investors may want to track how debt reduction affects liquidity.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
